HOME >> MEDICINE >> NEWS
Cure Rate Soars For Some AML Patients Receiving High-Dose Drug

COLUMBUS, Ohio -- A drug given at levels substantially higher than the standard dose can cure nearly five times as many patients who have a certain type of acute myeloid leukemia (AML), new research shows.

The study revealed that 78 percent of patients with “core binding factor” AML who received the drug cytarabine at high dose were in complete remission five years after treatment (and therefore potentially cured) compared to only 16 percent who received the standard dose.

“It is truly remarkable to achieve a cure rate of over 75 percent in a subgroup of adult leukemia patients; this rate approaches that for some types of childhood leukemia,” said Clara Bloomfield, director of Ohio State University's Comprehensive Cancer Center and William G. Pace III Professor of Cancer Research.

“Because high-dose cytarabine is quite toxic, especially for older people, we want to use it only with those patients who will benefit. These results tell us which patients we can cure, and which ones should receive other therapy.”

The finding is considered particularly strong because the study had followed patients for more than seven years after treatment; most such studies rely on models to project estimates of five-year remission rates.

The study, which was led by Bloomfield, appeared in the September issue of the journal Cancer Research. It involved 285 newly diagnosed AML patients aged 16 and older who were in remission. During the second phase of their treatment, a phase known as “intensification therapy,” the patients were randomly assigned to receive cytarabine at either standard dose (100 milligrams per square meter
'"/>

Contact: Clara Bloomfield
bloomfield-1@medctr.osu.edu
614-293-7518
Ohio State University
29-Oct-1998


Page: 1 2 3

Related medicine news :

1. Patients newly diagnosed with HIV are more likely to enter outpatient care with case management
2. Patients with cancer have highly increased risk for blood clots
3. Patients with previous heart attacks may not benefit from pacemaker implant
4. Patients with cancer detected on screening mammography undergo less toxic treatment
5. Patients with moderate or severe hand dermatitis responsive to drug therapy
6. Patients with abdominal trauma at risk for intra-abdominal infections following surgery
7. Patients who are intubated prior to hospital arrival fare worse find Pitt researchers
8. Patients undergoing weight loss surgery have high rates of H pylori bacteria
9. Patients with chronic sinus do not necessarily develop antibiotic resistance
10. Plastic surgeons honor Patients of Courage overcoming difficult obstacles, inspiring others
11. Patients with severe depression improve using guidelines developed by UT Southwestern researchers

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cure Rate Soars For Some AML Patients Receiving High Dose Drug

(Date:9/3/2015)... ... September 03, 2015 , ... E-Volve Health, ... leading national healthcare solutions organization, to provide electronic medical record (EMR) consulting services ... Amerinet members will receive negotiated pricing on E-Volve Health’s Epic EMR consulting, custom ...
(Date:9/3/2015)... ... September 03, 2015 , ... Mayo ... Indianapolis, have chosen Center for Hospice Care (CHC) for physician Hospice and ... at CHC as part of fulfilling their requirements for obtaining national Board Certification ...
(Date:9/3/2015)... ... 2015 , ... DriButts, a non-profit organization dedicated to helping ... Group to manufacture a long-lasting reusable diaper for warm weather climates where there ... 600 DriButts Diapers to rural areas of Haiti during a trip scheduled for ...
(Date:9/3/2015)... ... September 03, 2015 , ... Results of a ... Healthcare Research and Policy Analysis has found physician leadership development training programs to ... percent of respondents said their organizations conduct some kind of physician leadership development ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... care community to be situated at 4400 Columbine Drive in Bellingham, Washington. Silverado ... 2016, and has been carefully designed to serve up to 80 people living ...
Breaking Medicine News(10 mins):Health News:E-Volve Health to Offer EMR Consulting Solutions to Amerinet Members 2Health News:Physicians from Mayo Clinic and Indiana University to Complete Hospice & Palliative Medicine Training at Center for Hospice Care 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 2Health News:DriButts Diapers Rely on Slingshot Help in Haiti 3Health News:Survey finds growing movement for physician leadership training 2Health News:Survey finds growing movement for physician leadership training 3Health News:Site Dedication Ceremony to Celebrate New Silverado Memory Care Community 2
(Date:9/3/2015)... 2015 Research and ... of the "Global Craniomaxillofacial (CMF) Devices Market ... The global craniomaxillofacial devices market to grow at ... report covers the present and future scenario of ... calculate the market size, we use revenues generated ...
(Date:9/3/2015)... , Sept. 3, 2015 HeartWare International, ... of less invasive, miniaturized circulatory support technologies that are ... that its President and Chief Executive Officer, Doug ... Wells Fargo Healthcare Conference at 8:50 a.m. ET on ... 9-10, 2015 at The Hyatt Regency, Boston ...
(Date:9/3/2015)... Sept. 3, 2015 Research and Markets ( ... "Investigation Report on China Olmesartan Market, 2010-2019" report ... medoxomil was successfully developed by Sankyo Pharmaceuticals Co., Ltd ... olmesartan medoxomil was approved by FDA to enter the ... best- selling drug in the world after it succeeded ...
Breaking Medicine Technology:Global Craniomaxillofacial (CMF) Devices Market 2015-2019 - Product Innovation and Cost Reduction a Key Market Trend 2HeartWare Presentation At The 2015 Wells Fargo Healthcare Conference To Be Webcast 2China Olmesartan Investigation Market Report 2010-2019 2
Cached News: